Acute Management of Transient Ischemic Attack (TIA)
Start dual antiplatelet therapy with aspirin and clopidogrel immediately for this patient who has experienced a TIA with complete symptom resolution.
Antiplatelet Therapy for TIA
This 75-year-old man has experienced a classic TIA (transient ischemic attack) with complete resolution of neurological symptoms and a negative CT scan ruling out hemorrhage. The priority is preventing early stroke recurrence, which is highest in the first days to weeks after TIA.
Dual antiplatelet therapy (aspirin plus clopidogrel) is the correct choice for acute TIA management because:
- The patient presents within the critical early window when stroke risk is maximal (up to 20% risk in the first 90 days, with highest risk in the first week) 1
- CT scan has excluded hemorrhage, making antiplatelet therapy safe to initiate
- Dual antiplatelet therapy has been shown to reduce early recurrent stroke risk more effectively than aspirin monotherapy when started acutely after TIA
Why Not Aspirin Alone?
Aspirin monotherapy is appropriate for long-term secondary prevention but is suboptimal in the acute phase immediately following TIA when stroke risk is highest 1. The question of "aspirin versus clopidogrel versus both" is answered by timing: dual therapy acutely, then transition to monotherapy for chronic management.
Why Not Ticagrelor?
While ticagrelor is an option, the question specifically asks about the choices provided. Among the options given, aspirin plus clopidogrel represents the evidence-based acute intervention.
Blood Pressure Management Considerations
Do not aggressively lower blood pressure acutely in this patient despite the reading of 165/100 mmHg:
- In the acute TIA/stroke setting, permissive hypertension is appropriate to maintain cerebral perfusion 1
- Blood pressure lowering should be delayed 7-14 days after TIA unless there is hypertensive emergency 1
- Target blood pressure for this diabetic patient long-term should be <130/80 mmHg, but this is addressed after the acute period 1, 2
Risk Factor Management (Subacute Phase)
Once the acute period has passed, comprehensive cardiovascular risk reduction should be implemented:
Antihypertensive Therapy
- Start ACE inhibitor or ARB as first-line agent, particularly given his diabetes 1, 3
- Target BP <130/80 mmHg for diabetic patients 1, 2
- Most patients require combination therapy to achieve goal 3, 4
Lipid Management
- Initiate statin therapy regardless of baseline LDL levels for atherothrombotic TIA 1
- Target LDL <100 mg/dL 1
Diabetes Control
- Maintain fasting glucose <126 mg/dL (7 mmol/L) 1
- Optimize glycemic control with diet, exercise, and medications as needed 1
Lifestyle Modifications
- Smoking cessation if applicable 1
- Weight reduction if BMI >25 1
- Regular physical activity (at least 3-4 times weekly) 1
- Dietary modifications including salt restriction 1
Common Pitfalls to Avoid
- Do not delay antiplatelet therapy waiting for additional workup—start immediately once hemorrhage is excluded
- Do not aggressively lower blood pressure acutely—this can worsen cerebral perfusion and increase stroke risk
- Do not use aspirin monotherapy alone in the acute setting when dual therapy is indicated
- Do not forget to transition from dual antiplatelet therapy to monotherapy after the acute period (typically 21-90 days depending on protocol)